[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant

1987 Prophylaxis of Acute Gvhd Using Stromal Cell Therapy: Preliminary Results After Administration of Single or Multiple Doses of Multistem® in a Phase I Trial

Program: Oral and Poster Abstracts
Session: 722. Clinical Allogeneic Transplantation - Acute and Chronic GVHD, Immune Reconstitution: Poster I
Saturday, December 10, 2011, 5:30 PM-7:30 PM
Hall GH (San Diego Convention Center)

Richard T. Maziarz, MD1, Timothy deVos, M.D.2*, Carlos Bachier, MD3, Steven C. Goldstein, MD4, Jose F. Leis, MD, PhD5*, Robert Perry, B.S.6*, Robert Deans, PhD7, Wouter J Van't Hof, PhD7* and Hillard M. Lazarus, MD8

1Oregon Health and Science University, Portland, OR
2Hematology, Katholieke Universiteit Leuven, Lueven, Netherlands
3Texas Transplant Institute, San Antonio, TX
4Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
5Hematology/Oncology, Mayo Clinic Arizona, Scottsdale, AZ
6Manufacturing, Athersys, Inc., Cleveland, OH
7Regenerative Medicine, Athersys, Inc., Cleveland, OH
8Univ. Hospitals of Cleveland, Comprehensive Cancer Center, Cleveland, OH

Background. MultiStem®, a multipotent adult progenitor cells (MAPC) collection, is an immune-modulatory, bone marrow-derived adult adherent allogeneic stromal cell product manufactured to large scale, assuring consistency of universal donor cell product during clinical evaluation. Pre-clinical studies showed safety of IV infusion and survival benefit in a haploidentical transplantation rat model of acute GVHD (Kovacsovics 2008, 2009).

Methods. An open label Phase I clinical dose escalation study is being conducted with the primary goal to assess safety of MAPC as an adjunct treatment for human subjects undergoing myeloablative allogeneic HSCT for hematologic malignancies. Patients have been enrolled for MultiStem® administration as a single dose or in multiple weekly doses. Infusional toxicity and RRTs are assessed for 30 days following the last study drug dose administration. Secondary endpoints include incidence of acute GVHD, infection and survival through day 100. Dose escalation is guided by the Continual Reassessment Method (CRM).

Results. In the single dose arm, 18 patients with AML (9), MDS (4), CML (3) and ALL (2) from 5 clinical centers were administered MultiStem® IV at 1, 5, or 10 million cells per kg at day 2 after allogeneic HSCT. There was no observed infusional toxicity. Two patients experienced Bearman RRTs (Gr 3 mucositis; Gr 3 renal & pulmonary failure) deemed unrelated to study product. Engraftment occurred in all 18 patients. The median time to neutrophil engraftment for related (n=7) and unrelated (n=11) HSCT was 15 days (range, 12-16 days) and 14 days (range, 11-25 days), respectively. The 100-day cumulative incidence of Grade II-IV and III-IV GVHD was 28% and 6% (n=18). In the highest MultiStem® dose group (n=9) there was no grade III-IV GVHD, and only one case of grade II GVHD, which subsequently resolved with treatment. 17/18 patients have been enrolled in the multidose arm. Results of safety endpoints and interim results of all secondary endpoints of repeated MultiStem® administrations following HSCT will be presented.

Conclusion. Single dose administration of MultiStem® is well-tolerated, without observation of infusional toxicity or graft failure. Together with the observed low incidence of severe aGVHD, these findings are supportive of the concept that stromal stem cell therapy is safe and may be harnessed as an efficacious therapeutic option for acute GVHD prophylaxis following HSCT.

Figure 1:  Cumulative incidence of acute GVHD after administration of MAPC on Day 2 after conventional allogeneic HSCT in setting of tacrolimus & methotrexate GVHD prophylaxis.

 

Disclosures: Maziarz: Athersys, Inc: Patents & Royalties, Research Funding. Perry: Athersys, Inc.: Employment. Deans: Athersys, Inc: Employment. Van't Hof: Athersys, Inc.: Employment.

<< Previous Abstract | Next Abstract

*signifies non-member of ASH